Interpreting SPRINT: How low should you go?

George Thomas; Joseph V Nally; Marc A Pohl

doi:10.3949/ccjm.83a.15175

Interpreting SPRINT: How low should you go?

Cleve Clin J Med. 2016 Mar;83(3):187-95. doi: 10.3949/ccjm.83a.15175.

Authors

George Thomas^{1

2

3}, Joseph V Nally^{4

5}, Marc A Pohl^{6

7}

Affiliations

¹ Director, Center for Blood Pressure Disorders, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Cleveland, OH, USA. E-mail: [email protected].
² Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
³ Cleveland Clinic Site Principal Investigator, Systolic Blood Pressure Intervention Trial (SPRINT).
⁴ Director, Center for Chronic Kidney Disease, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
⁵ Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
⁶ Ray W. Gifford Chair in Hypertension, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
⁷ Chair, Clinical Management Committee, Irbesartan Diabetic Nephropathy Trial.

PMID: 26974989
DOI: 10.3949/ccjm.83a.15175

Abstract

The Systolic Blood Pressure Intervention Trial (SPRINT) found evidence of cardiovascular benefit with intensive lowering of systolic blood pressure (goal < 120 mm Hg) compared with the currently recommended goal (< 140 mm Hg) in older patients with cardiovascular risk but without diabetes or stroke. This article reviews the trial design and protocol, summarizes the results, and briefly discusses the implications of these results.

Publication types

Review

MeSH terms

Antihypertensive Agents / therapeutic use*
Blood Pressure / physiology*
Humans
Hypertension / drug therapy*
Hypertension / physiopathology
Randomized Controlled Trials as Topic*
Treatment Outcome

Substances

Antihypertensive Agents